Fennec Q3 2023: PEDMARK revenue $6.5M (+96% QoQ); UK approval for PEDMARQSI

FENNEC PHARMACEUTICALS INC.

2023-Q3 EPS reported -$0.50 revenue$11,517,000

PEDMARK net product revenue $6.5M in Q3 2023, up 96% from $3.3M in Q2 2023.
Net loss narrowed to $1.9M ($0.07/share) from $8.1M ($0.31) in Q3 2022.
Received UK MHRA approval for PEDMARQSI in October 2023.
Cash and equivalents $12.4M at Sept 30, 2023; sufficient for at least 12 months.
Gross profit $6.2M; selling & marketing expenses $3.4M for U.S. and EU launch prep.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

FENNEC PHARMACEUTICALS INC. reported the third quarter ended September 30, 2023 results: revenue $6.5 million, net income $1.9 million ($0.07 per share), EPS $0.07 per share.

Period: the third quarter ended September 30, 2023
Revenue: $6.5 million
Net income: $1.9 million ($0.07 per share)
EPS: $0.07 per share
Result: reported results

Exact text from the filing

EXHIBIT 99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ PEDMARK ® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October 2023 by the Medicines and

View on SEC.gov

493 earnings releases filed in the last 30 days. Browse all earnings releases →

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-114905

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.